{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:17:03Z","timestamp":1778246223593,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.transproceed.2025.04.005","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T07:22:28Z","timestamp":1745911348000},"page":"810-815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alirocumab in Adult Patients With Hyperlipidemia After Liver Transplantation: A Short-term Observation"],"prefix":"10.1016","volume":"57","author":[{"given":"Tieyan","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangxun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.transproceed.2025.04.005_bib0001","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1590\/0102-6720201600040008","article-title":"Dietary management for dyslipidemia in liver transplant recipients[J]","volume":"29","author":"Pinto","year":"2016","journal-title":"Arq Bras Cir Dig"},{"key":"10.1016\/j.transproceed.2025.04.005_bib0002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.atherosclerosis.2016.02.006","article-title":"The prevalence, awareness, treatment and control of dyslipidemia among adults in China[J]","volume":"248","author":"Pan","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.transproceed.2025.04.005_bib0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0735-1097(93)90814-H","article-title":"24th Bethesda conference: cardiac transplantation. Task Force 5: complications[J]","volume":"22","author":"Miller","year":"1993","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.transproceed.2025.04.005_bib0004","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/tri.13010","article-title":"Cardiovascular disease risk in patients receiving organ transplantation: a national cohort study[J]","volume":"30","author":"Tsai","year":"2017","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.transproceed.2025.04.005_bib0005","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.0000151805.86933.35","article-title":"Drug therapy in the heart transplant recipient: part IV: drug-drug interactions[J]","volume":"111","author":"Page","year":"2005","journal-title":"Circulation"},{"issue":"Pt 2","key":"10.1016\/j.transproceed.2025.04.005_bib0006","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1042\/bj2750501","article-title":"Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis[J]","volume":"275","author":"Princen","year":"1991","journal-title":"Biochem J"},{"issue":"2S Suppl 1","key":"10.1016\/j.transproceed.2025.04.005_bib0007","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/TP.0000000000001693","article-title":"mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis[J]","volume":"102","author":"Kurdi","year":"2018","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.transproceed.2025.04.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14228","article-title":"Mtor inhibitors associated with higher cardiovascular adverse events-A large population database analysis[J]","volume":"35","author":"Nguyen","year":"2021","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2025.04.005_bib0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12265-016-9719-8","article-title":"Sirolimus therapy is associated with elevation in circulating PCSK9 levels in cardiac transplant patients[J]","volume":"10","author":"Simha","year":"2017","journal-title":"J Cardiovasc Transl Res"},{"issue":"6","key":"10.1016\/j.transproceed.2025.04.005_bib0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2017.12.005","article-title":"Long-term sirolimus for primary immunosuppression in heart transplant recipients[J]","volume":"71","author":"Asleh","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.transproceed.2025.04.005_bib0011","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1016\/j.transproceed.2011.08.074","article-title":"Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen[J]","volume":"43","author":"Spinelli","year":"2011","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.transproceed.2025.04.005_bib0012","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/ndt\/gfh739","article-title":"Efficacy and safety of tacrolimus compared with cyclosporin a microemulsion in renal transplantation: 2 year follow-up results[J]","volume":"20","author":"Kramer","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.transproceed.2025.04.005_bib0013","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.healun.2005.11.452","article-title":"Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients[J]","volume":"25","author":"Kobashigawa","year":"2006","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.transproceed.2025.04.005_bib0014","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab[J]","volume":"146","author":"Hagstrom","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.transproceed.2025.04.005_bib0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","article-title":"Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the Fourier randomized clinical trial[J]","volume":"6","author":"Deedwania","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.transproceed.2025.04.005_bib0016","first-page":"1408","article-title":"Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial[J]","volume":"44","author":"Schwartz","year":"2023","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.transproceed.2025.04.005_bib0017","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"alirocumab and cardiovascular outcomes after acute coronary syndrome[J]","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2025.04.005_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.953040","article-title":"Optimized treatment of refractory hypercholesterolemia in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia with alirocumab (OPTIMIZE)[J]","volume":"9","author":"Sudano","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.transproceed.2025.04.005_bib0019","first-page":"1401","article-title":"[Efficacy and safety of the use of alirocumab in real clinical practice][J]","volume":"94","author":"Korneva","year":"2023","journal-title":"Ter Arkh"},{"issue":"1","key":"10.1016\/j.transproceed.2025.04.005_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.acvd.2022.10.004","article-title":"Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE study[J]","volume":"116","author":"Henry","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"issue":"7","key":"10.1016\/j.transproceed.2025.04.005_bib0021","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cardfail.2021.02.018","article-title":"PCSK9 inhibitors in heart transplant patients: safety, efficacy, and angiographic correlates[J]","volume":"27","author":"Sammour","year":"2021","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.transproceed.2025.04.005_bib0022","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ndt\/gfr238","article-title":"Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study[J]","volume":"27","author":"Claes","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.transproceed.2025.04.005_bib0023","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MOL.0000000000000363","article-title":"Hyperlipidaemia in immunosuppression[J]","volume":"27","author":"Kockx","year":"2016","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"10.1016\/j.transproceed.2025.04.005_bib0024","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s43440-020-00090-6","article-title":"Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1[J]","volume":"72","author":"Sato","year":"2020","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.transproceed.2025.04.005_bib0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10741-022-10255-5","article-title":"PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis[J]","volume":"28","author":"Jennings","year":"2023","journal-title":"Heart Fail Rev"},{"issue":"12","key":"10.1016\/j.transproceed.2025.04.005_bib0026","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.recesp.2019.05.014","article-title":"Treatment of hypercholesterolemia with PCSK9 inhibitors in heart transplant recipients. First Experience in Spain[J]","volume":"72","author":"Groba-Marco","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"2","key":"10.1016\/j.transproceed.2025.04.005_bib0027","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2012.04.006","article-title":"Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia[J]","volume":"223","author":"Abifadel","year":"2012","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.transproceed.2025.04.005_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210373","article-title":"Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation[J]","volume":"14","author":"Kuhl","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.transproceed.2025.04.005_bib0029","article-title":"Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation[J]","volume":"35","author":"Moayedi","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.transproceed.2025.04.005_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1206551","article-title":"Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study[J]","volume":"10","author":"Banach","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"18","key":"10.1016\/j.transproceed.2025.04.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029216","article-title":"Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the odyssey outcomes trial[J]","volume":"12","author":"Goodman","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.transproceed.2025.04.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials[J]","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.transproceed.2025.04.005_bib0033","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9[J]","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.transproceed.2025.04.005_bib0034","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jacl.2016.05.004","article-title":"Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report[J]","volume":"10","author":"Nagashima","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.transproceed.2025.04.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/7362551","article-title":"An updated meta-analysis for safety evaluation of alirocumab and evolocumab as PCSK9 inhibitors[J]","volume":"2023","author":"Choi","year":"2023","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"10.1016\/j.transproceed.2025.04.005_bib0036","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.4244\/EIJ-D-23-00201","article-title":"Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial[J]","volume":"19","author":"Bar","year":"2023","journal-title":"EuroIntervention"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525002131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525002131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:36:20Z","timestamp":1778243780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134525002131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0041134525002131"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.04.005","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alirocumab in Adult Patients With Hyperlipidemia After Liver Transplantation: A Short-term Observation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}